Description
Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE), isolated from Thymalin through fractionation and developed as a defined immune system bioregulator within the Khavinson series. At approximately 275 Da and just two amino acids, it is the smallest compound in this catalog. Its minimal size supports rapid cellular access and makes it a tractable model for studying how the shortest possible peptide sequences encode biologically meaningful tissue-specific information. Vilon targets thymic tissue and T-lymphocyte populations. Its documented mechanism of action in aged immune tissue is primarily anti-apoptotic rather than proliferative. T-helper activation through suppression of programmed cell death, not increased cell division, which distinguishes it from other immune compounds in the specialty research peptide index.
Key Characteristics
- Anti-apoptotic T-helper activation is the defining mechanistic distinction. Vilon activates T-helper populations in aged splenic tissue primarily by reducing apoptosis of existing immune cells rather than by stimulating proliferation. This apoptosis-suppression pathway differs from both Thymogen’s gene regulatory approach and Thymosin Alpha 1’s TLR-mediated innate immune signaling
- CD4 and CD5 surface marker expression induction on thymocytes drives differentiation toward the T-helper lineage. This surface marker specificity provides a defined flow cytometry endpoint for laboratory studies. It makes Vilon a practical tool for thymocyte differentiation research
- Smallest compound in the catalog by molecular weight. 275 Da is well below the threshold that typically limits membrane permeability; this property is itself a research variable in studies examining minimum peptide length requirements for intranuclear gene regulatory activity
- Shares thymic origin with Thymogen (EW) but through distinct mechanisms. Both are Thymalin-derived dipeptides; Thymogen works through GGAG DNA binding and cAMP/cGMP modulation, while Vilon works through apoptosis suppression and CD4/CD5 differentiation induction; using both in the same experimental design enables mechanistic dissection of Thymalin’s composite activity
- Chromatin decondensation in lymphocytes has been documented — an effect shared with Livagen. Though Vilon’s chromatin activity is less pronounced and does not extend to pericentromeric heterochromatin regions as Livagen’s does, providing a direct comparison point in chromatin biology research
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. Despite its very small molecular weight, Vilon is susceptible to peptide bond hydrolysis under suboptimal conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Vilon?
Vilon (KE) is a synthetic dipeptide, just lysine and glutamic acid, isolated from the Thymalin complex. It is developed as a defined immune system bioregulator. At 275 Da, it is the smallest compound in this index. It is studied for T-helper activation through anti-apoptotic signaling in aged immune tissue, CD4/CD5 differentiation marker induction on thymocytes, and chromatin structure modulation in lymphocyte populations.
How does Vilon’s mechanism differ from Thymogen’s?
Both are thymus-derived dipeptides from the Thymalin complex. Thymogen (EW) acts primarily through GGAG DNA binding and cAMP/cGMP nucleotide balance modulation — a gene regulatory approach. Vilon (KE) acts primarily through anti-apoptotic T-helper activation and CD4/CD5 surface marker induction — a cell survival and differentiation approach. These distinct mechanisms make the two dipeptides complementary research tools for dissecting how Thymalin’s combined immune activity is distributed across its component peptides.
What does Vilon’s minimal size tell researchers about peptide bioregulator biology?
Vilon represents the minimal functional unit of the Khavinson bioregulator class. That a two-amino-acid sequence can produce tissue-specific gene expression changes and measurable immune cell effects is a mechanistically significant finding — it constrains hypotheses about minimum peptide length requirements for biological specificity.
